Oncolytics Biotech Inc.

499 articles with Oncolytics Biotech Inc.

• Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

  3/3/2022

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the quarter and year ended December 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted.

• Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

  2/22/2022

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2021.

• Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

  2/2/2022

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the pancreatic cancer cohort of the phase 1/2 GOBLET study following evaluation by the study's Data Safety Monitoring Board (DSMB).

• Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

  1/27/2022

   Oncolytics Biotech today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.

• Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

  1/20/2022

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI).

• Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 Outlook

  1/11/2022

  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders.

• Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer

  12/21/2021

  Dr. Heineman has over two decades of experience successfully leading clinical development programs and previously served as Oncolytics' Global Head of Clinical Development and Operations.

• Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting

  12/15/2021

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced preclinical data demonstrating the synergistic anti-leukemic effects of pelareorep combined with the chemotherapeutic agent azacitidine.

• Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium

  12/10/2021

  Oncolytics Biotech ®  Inc. announced a positive interim safety update from the investigator-sponsored, phase 2 IRENE trial in a poster presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS).

• Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium

  11/19/2021

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present an update on the Phase 2 IRENE trial in a poster at the 2021 San Antonio Breast Cancer Symposium (SABCS).

• Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results

  11/5/2021

   Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended September 30, 2021.

• Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers

  11/3/2021

  Oncolytics Biotech® Inc. today announced that the first patient has been dosed in the phase 1/2 GOBLET trial.

• Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter 2021 Financial Results and Operational Highlights

  10/19/2021

  Oncolytics Biotech® Inc. announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the third quarter of 2021.

• Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

  10/14/2021

  Trial is designed to advance pelareorep's clinical development in China , the world's second-largest pharmaceutical market

• Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy

  9/20/2021

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model.

• 

  Canada Gaining in the Global War for Biotech Talent

  8/20/2021

  Toronto saw the biggest growth in technology jobs of any North American city between 2015 and 2020, while Vancouver, British Columbia also made the top five.

• Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference

  8/6/2021

  Oncolytics Biotech® Inc. announced that the Company will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference, which is taking place virtually from August 10-12, 2021.

• Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results

  8/6/2021

  Oncolytics Biotech® Inc. announced its financial results and development highlights for the quarter ended June 30, 2021.

• Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Operational Highlights

  7/22/2021

  Oncolytics Biotech® Inc. announced that it will host a conference call and webcast on Friday, August 6, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the second quarter 2021.

• Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference

  6/30/2021

  Oncolytics Biotech® Inc. announced that the Company will present a corporate overview at the Ladenburg Thalmann Healthcare Conference, which is taking place virtually from July 13-14, 2021.